Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe active lupus, a retrospective study shows.

A 2-month-old boy was brought to the clinic with a 2-week history of red spots on his face. On examination, annular plaques with edematous borders and central crusting were observed on his face, ...